DRNA Historical Earnings image   This DRNA historical earnings page last updated 11/11/2021
DRNA Historical Revenue
PeriodHistorical Earnings DateGAAP
Q3 202111/9/20210.06B
Q2 20218/9/20210.04B
Q1 20215/6/20210.05B
Q4 20202/25/20210.04B
Q3 202011/5/20200.05B
Q2 20208/6/20200.04B
Q1 20205/7/20200.03B
Q4 20192/27/20200.01B
Q3 201911/7/20190.01B
Q2 20198/8/20190.01B
Q1 20195/9/20190.00B
Q4 20183/11/20191.54M
Q3 201811/5/20181.54M
Q2 20188/8/20181.54M
Q1 20185/14/20181.54M
Q4 20173/8/20181.42M
Q3 201711/2/2017474000
Q2 20178/10/2017252000
Q1 20175/8/2017133000
Q4 20163/30/2017133000
Q3 201611/7/2016162000
Q2 20168/4/2016NA
Q1 20165/9/2016NA
Q4 20153/10/2016NA
Q3 201511/10/2015NA
Q2 20158/6/2015184000
Q1 20155/11/2015NA
Q4 20143/12/2015NA
Q3 201411/6/2014NA
Q2 20148/7/2014NA
Q1 20145/13/2014NA
Q4 20133/27/2014NA
DRNA Historical Earnings EPS
Data adjusted for DRNA split history

PeriodHistorical Earnings DateGAAP
Q3 202111/9/2021-0.220
Q2 20218/9/2021-0.530
Q1 20215/6/2021-0.390
Q4 20202/25/2021-0.490
Q3 202011/5/2020-0.290
Q2 20208/6/2020-0.430
Q1 20205/7/2020-0.310
Q4 20192/27/2020-0.580
Q3 201911/7/2019-0.450
Q2 20198/8/2019-0.350
Q1 20195/9/2019-0.380
Q4 20183/11/2019-0.29
Q3 201811/5/2018-0.35
Q2 20188/8/2018-0.68
Q1 20185/14/2018-0.3
Q4 20173/8/2018-0.9
Q3 201711/2/2017-0.92
Q2 20178/10/2017-0.86
Q1 20175/8/2017-0.68
Q4 20163/30/2017-0.68
Q3 201611/7/2016-0.68
Q2 20168/4/2016-0.75
Q1 20165/9/2016-0.76
Q4 20153/10/2016-0.76
Q3 201511/10/2015-0.71
Q2 20158/6/2015-0.72
Q1 20155/11/2015-0.66
Q4 20143/12/2015-0.82
Q3 201411/6/2014-0.54
Q2 20148/7/2014-0.6
Q1 20145/13/2014-0.56
Q4 20133/27/2014-0.2
Quotes delayed 20 minutes

Email EnvelopeFree DRNA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Dicerna Pharmaceuticals (DRNA) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

DRRX Past Earnings
DSGN Past Earnings
DTIL Past Earnings
DVA Past Earnings
DVAX Past Earnings
DXCM Past Earnings
DYAI Past Earnings
DYN Past Earnings
EAR Past Earnings
EBS Past Earnings
What was the record high DRNA historical earnings result?
In terms of earnings or revenue, what is the best DRNA historical earnings result that Dicerna Pharmaceuticals has ever posted, and when?

✔️Accepted answer: Within our data set, the highest DRNA historical earnings result was set in Q4 2013, when Dicerna Pharmaceuticals posted results of -0.2/share. The most successful revenue quarter within our data set was Q3 2021 when Dicerna Pharmaceuticals reported revenue of 0.06B.

What was the lowest Dicerna Pharmaceuticals historical earnings result?
In terms of top line revenue or bottom line earnings per share, what was the lowest DRNA has reported, and when?

✔️Accepted answer: Within our data set, the lowest DRNA historical earnings result was set in Q3 2017, when Dicerna Pharmaceuticals posted results of -0.92/share. The smallest revenue quarter within our data set was Q2 2016 when Dicerna Pharmaceuticals reported revenue of NA.

On this page we presented the DRNA historical earnings date information for Dicerna Pharmaceuticals. Reviewing that DRNA Historical Earnings for the company, we see that the highest historical earnings result in our data set was in Q4 2013, when DRNA posted gaap of -0.2/share. Meanwhile the lowest DRNA historical earnings result was in Q3 2017, when DRNA posted gaap of -0.92/share. Moving to Dicerna Pharmaceuticalss historical revenue numbers, the largest revenue quarter in our data set was seen in Q3 2021 when DRNA reported 0.06B in revenue, while the smallest revenue quarter was Q2 2016 when DRNA reported NA in revenue.

For self directed investors doing their due diligence on DRNA or any other given stock, their research can benefit from looking into all of the Dicerna Pharmaceuticals historical earnings in our data set presented side by side on one page for ease of comparison. Reviewing this historical EPS information can help when projecting future earnings per share, as well as providing important context for pondering whether the historical earnings trajectory justifies the current stock value or not. That's why we bring you HistoricalEarnings.com to make it more convenient for investors to look into Dicerna Pharmaceuticals historical earnings, or the historical earnings information for any stock in our coverage universe. In your continued due diligence investigations, we hope you check out the further links included for historical PE studies, earnings surprises history as well as next earnings dates for DRNA. Thanks for visiting, and the next time you need to research DRNA historical earnings or those of another stock, we hope our site will come to your mind as your preferred historical earnings, revenue, and EPS research resource of choice.
 

DRNA Historical Earnings | www.HistoricalEarnings.com | Copyright © 2020 - 2021, All Rights Reserved

Nothing in HistoricalEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.